Pegargiminase
Information
- Drug Name
- Pegargiminase
- Description
- Entry(CIViC)
- 1
CIViC
Annotation
Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
---|---|---|---|---|---|---|
90% out of 700 sarcoma samples (comprising 45 hist... | ASS1 | ASS1 LOSS ASS1 LOSS | Sensitivity | true | CIViC Evidence | detail |
NCT ID | Status | Phase | Summary | Start date | Completion date |
---|---|---|---|---|---|
NCT04965714 | Withdrawn | Phase 2 | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | April 13, 2022 | February 10, 2023 |